Sébastien Charpentier

No ORCID on file · 2 papers in corpus · active 2021-2022

Study types

  • article 1
  • other 1

Condition tags

  • dysmenorrhea 2
  • adenomyosis 2
  • dyspareunia 2
  • mesh:D004414 1
  • mesh:D017699 1
  • mesh:D004412 1
other 2022
Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2021.09.019

RESEARCH QUESTION: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially suppressive dose (100 mg) for a furth…

article 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
Journal of clinical medicine ·doi:10.3390/jcm10245794

(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy m…